Recognizing that each person with type 2 diabetes is unique, AstraZeneca today
announced the launch of Fit2Me,
a free diet and lifestyle support program that allows people with this
complex disease to create a diabetes care plan that is custom fit to
their likes and dislikes. Fit2Me is the first multi-platform,
customizable diabetes platform offered in the suite of AstraZeneca
patient support programs.
Fit2Me is the only diabetes support program to offer the guidance and
encouragement of “digital coaches” who help users through the process
and celebrating successes along the way. Utilizing an interactive gaming
platform to design and implement their personalized plans, people make
meal and exercise choices and tradeoffs custom fit to their preferences.
In addition, no other diabetes support program has as robust a recipe
and activity database as Fit2Me, with more than 10,000 diabetes-friendly
recipes and over 500 physical activities and exercises.
“For our adult patients with type 2 diabetes, where our emphasis is on
confident self-management and empowerment, a major challenge is finding
a way to make diet and lifestyle changes that work for them,” said James
R. Gavin III, MD, PhD, clinical professor of medicine at Emory
University School of Medicine, and CEO and chief medical officer at
Healing Our Village, Inc. “Unlike other programs, Fit2Me is a
compelling, fresh approach that strengthens self-management and lets
people make choices based on their individual tastes and activity levels
– a reflection of the reality that one size doesn’t fit all.”
Fit2Me focuses on four key areas of diabetes management – food,
activity, support team and treatment support.
-
Food – Fit2Me has a database of more than 10,000
diabetes-friendly recipes, based on criteria from the American
Diabetes Association. After providing their likes and dislikes when it
comes to cuisine and ingredients, individuals receive their own
customized recipe selections allowing them to pick a single meal or
create a weekly meal plan.
-
Activity – Fit2Me has a database of more than 500 physical
activities and focused exercises, most of which have videos with
step-by-step instructions. Users can customize a personal activity
program based on their activity level and preferences, with exercises
covering lifestyle, cardio, strength and flexibility.
-
Support Team – Fit2Me offers each user a digital coach, whose
responses to questions help plan and celebrate successes. The program
offers users the opportunity to select from a number of digital
coaches to ensure they’re paired with the one that is best-suited to
motivate them.
-
Treatment Support – Fit2Me offers treatment and appointment
reminders, blood sugar trackers, and a personalized treatment kit that
includes information about type 2 diabetes and treatment options from
AstraZeneca that they can discuss with their doctor.
“We launched Fit2Me with the understanding that type 2 diabetes is a
multi-faceted, progressive disease that requires customized approaches
to treatment management,” said Topher Brooke, vice president, U.S.
Diabetes, AstraZeneca. “In addition to our diverse portfolio of diabetes
treatments, AstraZeneca has a long-term commitment to putting patients
first and providing people with custom fit diabetes solutions like
Fit2Me to help them better manage their condition today and in the
future.”
The program also rewards people with type 2 diabetes for being active
participants in generating their own positive outcomes, offering points
for visiting the site regularly and completing fun team challenges.
These points can be accumulated for entry into the Fit2Me sweepstakes
for chances to win prizes.
Learn more about Fit2Me at www.Fit2Me.com
and enter the unique promo code NEWS. As with any lifestyle program, it
is important for patients to remember to consult with their doctors
before beginning any exercise or nutrition program.
AstraZeneca addresses medical needs across a wide spectrum of diabetes
patients at different stages of the disease. With a portfolio of seven
approved products and with other compounds in development, AstraZeneca
is ushering in a new era of innovative diabetes treatment options to
support individualized patient care. Current late-stage research
includes fixed-dose combinations for type 2 diabetes and novel
medications for type 1 diabetes. R&D efforts also aim to impact the
burden of diabetes by researching the underlying mechanisms of the
disease that could one day help lead to a cure.
Fit2Me Contest Rules
NO PURCHASE NECESSARY TO ENTER OR WIN. Sweepstakes ends 8/31/15 and is
subject to Entry Periods as outlined in the full Official Rules
available at www.fit2mecoach.com/#/sweepstakes-terms.
Open only to legal US residents in the 50 US States and the District of
Columbia who are 18 years of age or older at the time of entry. Void
outside the 50 US States, the District of Columbia, and where restricted
or prohibited by law.
About Type 2 Diabetes
Diabetes is estimated to affect 29.1 million people in the US and more
than 382 million people worldwide. The prevalence of diabetes is
projected to reach more than 592 million people worldwide by 2035. Type
2 diabetes accounts for approximately 90-95 percent of all cases of
diagnosed diabetes. Type 2 diabetes is a chronic disease
characterized by pathophysiologic defects leading to elevated glucose
levels. Significant unmet needs still exist, as many patients remain
inadequately controlled on their current glucose-lowering regimen.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of cardiovascular,
metabolic, respiratory, inflammation, autoimmune, oncology, infection
and neuroscience diseases. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca-us.com
3041105 10/14
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20141015005248r1&sid=ntxv4&distro=nx&lang=en)
Copyright Business Wire 2014